These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 30737965)
41. Coronary Access After Repeated Transcatheter Aortic Valve Implantation: A Glimpse Into the Future. Buzzatti N; Romano V; De Backer O; Soendergaard L; Rosseel L; Maurovich-Horvat P; Karady J; Merkely B; Ruggeri S; Prendergast B; De Bonis M; Colombo A; Montorfano M; Latib A JACC Cardiovasc Imaging; 2020 Feb; 13(2 Pt 1):508-515. PubMed ID: 31422142 [No Abstract] [Full Text] [Related]
42. Coronary Access After Transcatheter Aortic Valve Replacement in Patients With Bicuspid Aortic Valve: Lights and Shades. Tarantini G; Fabris T; Cardaioli F; Nai Fovino L JACC Cardiovasc Interv; 2019 Jun; 12(12):1190-1191. PubMed ID: 31153840 [No Abstract] [Full Text] [Related]
43. MitraClip and Transcatheter Aortic Valve Replacement in a Patient With Recurrent Heart Failure. Gandhi S; Natarajan MK; Chu V; Dokainish H; Mehta S; Velianou JL Circ Cardiovasc Interv; 2017 Sep; 10(9):. PubMed ID: 28893771 [No Abstract] [Full Text] [Related]
44. Emergency valve-in-valve transcatheter aortic valve replacement in a patient with degenerated bioprosthetic aortic stenosis and cardiogenic shock on veno-arterial extracorporeal membrane oxygenation. Summers MR; Mick S; Kapadia SR; Krishnaswamy A Catheter Cardiovasc Interv; 2018 Sep; 92(3):592-596. PubMed ID: 28296034 [TBL] [Abstract][Full Text] [Related]
45. A paradigm shift from surgical to transcutaneous aortic valve replacement (PARTNER 3 and Evolut Low Risk trials). Taggart DP Cardiovasc Res; 2019 Sep; 115(11):e107-e108. PubMed ID: 31436831 [No Abstract] [Full Text] [Related]
46. Performance of the Evolut-R 34 mm versus Sapien-3 29 mm in Transcatheter aortic valve replacement patients with larger annuli: Early outcome results of Evolut-R 34 mm as compared with Sapien-3 29 mm in patients with Annuli ≥26 mm. Eitan A; Witt J; Stripling J; Haselbach T; Rieß FC; Schofer J Catheter Cardiovasc Interv; 2018 Dec; 92(7):1374-1379. PubMed ID: 29521464 [TBL] [Abstract][Full Text] [Related]
54. The bailout transseptal approach during valve‑in‑valve transcatheter aortic valve implantation with difficult crossing of the degenerated Mitroflow bioprosthetic valve. Hudziak D; Ochała A; Gocoł R; Kozłowski M; Wojakowski W Kardiol Pol; 2021 Apr; 79(4):473-474. PubMed ID: 33723975 [No Abstract] [Full Text] [Related]
55. Stented within a stentless aortic valve. A simple surgical solution for the replacement of a stentless aortic bioprosthesis. Panagiotou M; Kogerakis N; Crockett JR; Economidou S Interact Cardiovasc Thorac Surg; 2010 Jan; 10(1):7-8. PubMed ID: 19805504 [TBL] [Abstract][Full Text] [Related]
56. The beginning of a new era in the field of percutaneous valvular interventions (PARTNER 3 and Evolut Low Risk trials). Dudek D Cardiovasc Res; 2019 Sep; 115(11):e105-e106. PubMed ID: 31436829 [No Abstract] [Full Text] [Related]
57. TAVR vs SAVR: Rising Expectations and Changing Indications for Surgery in Response to PARTNER II. Spadaccio C; Nappi F; Sablayrolles JL; Sutherland FWH Semin Thorac Cardiovasc Surg; 2017 Spring; 29(1):8-11. PubMed ID: 28684004 [TBL] [Abstract][Full Text] [Related]